BioSpace News Archive

Scinai Immunotherapeutics Ltd. announced that its primary creditor, the European Investment Bank, is currently considering favorably adjusting the terms of the EIB’s financial facility contract with the Company, in particular by extending the facility’s maturity.

Senti Biosciences, Inc. today announced four poster presentations at the Society for Immunotherapy of Cancer (SITC) Annual Meeting, being held November 1-5, 2023, in San Diego, CA.

Iovance Biotherapeutics, Inc. today announced the publication of abstracts for poster presentations reporting clinical data and trial design for tumor infiltrating lymphocyte (TIL) therapies at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting in San Diego, CA, November 1-5, 2023.

AffaMed Therapeutics announced positive top-line results from the Real-World Study conducted in the Boao Lecheng Pilot Zone in Hainan, China, to evaluate the safety and efficacy of DEXTENZA® (0.4 mg dexamethasone ophthalmic insert) for the treatment of ocular inflammation and pain following cataract surgery.

Complete Genomics announced at the American Society of Human Genetics Annual Meeting, Nov. 1-5, in Washington details on the commercial and technical momentum it has demonstrated in the last 10 months since launching in the United States market through new customers, partnerships and collaborations.

Compugen Ltd. (Nasdaq: CGEN) (TASE:CGEN) today announced it will present new data on its lead pre-clinical asset COM503, a potential first-in-class anti-IL18BP antibody in an oral presentation at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC), taking place 3-5 November 2023, San Diego, CA. Abstracts have been released by SITC today.

OncoHost, a technology company transforming the approach to precision medicine for improved patient outcomes, has developed a novel computational model for predicting significant immune-related adverse events (irAEs) in patients with non-small cell lung cancer (NSCLC) based on proteomic profiling of pre-treatment blood samples.

Kernal Biologics, Inc. (Kernal Bio) — a development-stage mRNA-technology company developing cancer therapeutics designed to improve patients’ survival rate and quality of life — today announced it is presenting a poster at the Society for Immunotherapy of Cancer 2023 Annual Meeting on Friday, November 3, 2023 in San Diego, CA.

M.S.Q. Ventures is pleased to announce that its client, BioLineRx Ltd., has entered into an exclusive license agreement with Guangzhou Gloria Biosciences Co., Ltd. and an associated investor for the development of motixafortide across all indications in Asia.

Lucid Diagnostics Inc. a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc., announced two longitudinal clinical registries which are collecting real-world clinical utility and clinical validity data on EsoGuard® Esophageal DNA testing for the detection of esophageal precancer.